Breakthroughs with NASH Management: What Do Gastroenterologists and Hepatologists Need to Know?
- CME / AMA PRA Category 1 Credit™
- MOC / ABIM MOC Part 2 Credit
WEBINAR DATE AND TIME
Tuesday, August 4, 2020
4:00 – 5:00 PM ET (3:00 – 4:00 PM CST / 1:00 – 2:00 PM PST)
Non-alcoholic steatohepatitis (NASH), an advanced form of non-alcoholic fatty liver disease (NAFLD), is a severe liver disorder with a rapidly progressive course that can lead to liver fibrosis, cirrhosis, and hepatocellular carcinoma. In order to prevent irreversible liver damage, patients with NASH should receive immediate treatment. However, distinguishing NASH from other liver disorders and identifying high-risk patients remain challenges, and there are limited treatment options once a patient is diagnosed. While there are no approved medical therapies for NASH, multiple investigational agents have shown promise in late-stage trials and are expected to be available for NASH treatment soon.
This activity, Breakthroughs with NASH Management: What Do Gastroenterologists and Hepatologists Need to Know? will provide clinicians with the most current guidance on NASH diagnostic strategies. Clinician learners will also receive information on the efficacy, safety, and potential use of novel agents in late-stage clinical investigation for the treatment of patients with NASH.
Welcome and Introduction
Understanding Optimal Evaluation of Patients with NASH
Staying Up-To-Date with the Latest NASH Advances
The intended audiences for this educational initiative are hepatologists and gastroenterologists involved in the assessment and management of adults with NASH.
This program is designed to address ACGME and NAM competencies, including delivering patient-centered care and practicing evidence-based medicine.
At the conclusion of this activity, participants should be able to:
- Implement guideline- and expert-recommended strategies to diagnose NASH and evaluate its severity
- Evaluate the safety and efficacy data for the NASH therapies in late-stage development
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine and Rockpointe. The Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The Penn State College of Medicine designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
ABIM MOC DESIGNATION STATEMENT
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
For ABIM MOC points, your information will be shared with the ABIM through PSU’s ACCME Program and Activity Reporting System (PARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.
Disclosures will be made known to participants prior to the activity.
INSTRUCTIONS FOR PARTICIPANTS AND OBTAINING CME CREDIT AND MOC POINTS
If you will be watching the webinar in a group setting, please note all group participants will need to register individually in order to complete the post-test and evaluation to receive credit.
Jointly provided by Penn State College of Medicine and Rockpointe
This program is supported by educational grant from Intercept Pharmaceuticals, Inc.
Breaking Down Long-Chain Fatty Acid Oxidation Disorder Treatment: Review of Current Care and the Latest Advances (Physicians)
Credits 1.00 (60 min)
Asthma Management in the Era of Targeted Therapy: Using Phenotype and Biomarkers to Individualize Management
Credits 1.00 (60 min)
Opioid Analgesics: Risk Evaluation and Mitigation Strategy (REMS)
Credits 3.00 (3 hrs)